Page 39 - காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In காரணிகள் அந்த இருக்கலாம் செயல்விளைவு உண்டுபண்ணு எதிர்கால Today - Breaking & Trending Today

Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine

Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose Vaccine efficacy observed in the overall study population was also generally consistent across subgroups defined by age, gender, race, ethnicity, . ....

United States , South Africa , Sylke Maas , Kathrinu Jansen , Chuck Triano , Amy Rose , Fosun Pharma , Head Of Vaccine Research Development , Drug Administration , Bayer Animal Health , Exchange Commission , Pfizer Inc , European Medicines Agency , Roche Group , New England Journal , Senior Vice President , Vaccine Research , Chief Medical Officer , African American , Emergency Use Authorization , Conditional Marketing Authorization Application , Breakthroughs That Change Patient Lives , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future ,

Investegate |BioNTech SE Announcements | BioNTech SE: Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine

BioNTech SE
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose
Vaccine efficacy observed in the overall study population was also generally consistent across subgroups defined by age, gender, race, ethnicity, baseline body mass index (BMI) or presence of other underlying co-morbidities ....

United States , South Africa , Sylke Maas , Kathrinu Jansen , Chuck Triano , Amy Rose , Fosun Pharma , Head Of Vaccine Research Development , Drug Administration , Bayer Animal Health , Exchange Commission , Pfizer Inc , European Medicines Agency , Roche Group , Announce Publication , Landmark Phase , New England Journal , European Medicines , Senior Vice President , Vaccine Research , Chief Medical Officer , African American , Emergency Use Authorization , Conditional Marketing Authorization Application , Breakthroughs That Change Patient , Annual Report ,